Display options
Cite
Nishino M, Ozaki M, Hegab AE, et al. Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. J Cancer. 2017;8(10):1774-1785doi: 10.7150/jca.19732.
Nishino, M., Ozaki, M., Hegab, A. E., Hamamoto, J., Kagawa, S., Arai, D., Yasuda, H., Naoki, K., Soejima, K., Saya, H., & Betsuyaku, T. (2017). Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. Journal of Cancer, 8(10), 1774-1785. https://doi.org/10.7150/jca.19732
Nishino, Makoto, et al. "Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma." Journal of Cancer vol. 8,10 (2017): 1774-1785. doi: https://doi.org/10.7150/jca.19732
Nishino M, Ozaki M, Hegab AE, Hamamoto J, Kagawa S, Arai D, Yasuda H, Naoki K, Soejima K, Saya H, Betsuyaku T. Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. J Cancer. 2017 Jul 01;8(10):1774-1785. doi: 10.7150/jca.19732. eCollection 2017. PMID: 28819374; PMCID: PMC5556640.
Copy Download .nbib Format: NLM
Share it on

J Cancer. 2017 Jul 01;8(10):1774-1785. doi: 10.7150/jca.19732. eCollection 2017.

Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma.

Journal of Cancer

Makoto Nishino, Mari Ozaki, Ahmed E Hegab, Junko Hamamoto, Shizuko Kagawa, Daisuke Arai, Hiroyuki Yasuda, Katsuhiko Naoki, Kenzo Soejima, Hideyuki Saya, Tomoko Betsuyaku

Affiliations

  1. Division of Pulmonary Medicine, Department of Medicine, and.
  2. Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

PMID: 28819374 PMCID: PMC5556640 DOI: 10.7150/jca.19732

[No abstract available.]

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

  1. Front Immunol. 2015 Apr 08;6:154 - PubMed
  2. PLoS One. 2013;8(3):e57020 - PubMed
  3. Oral Oncol. 2013 Apr;49(4):306-13 - PubMed
  4. Oncotarget. 2015 Sep 29;6(29):26633-50 - PubMed
  5. PLoS One. 2010 Nov 19;5(11):e14062 - PubMed
  6. Free Radic Res. 2010 May;44(5):479-96 - PubMed
  7. Cancer Res. 2005 Jul 1;65(13):5506-11 - PubMed
  8. J Immunol Res. 2014;2014:796856 - PubMed
  9. Stem Cell Res. 2015 Jul;15(1):109-21 - PubMed
  10. J Immunother Cancer. 2016 Aug 16;4:48 - PubMed
  11. Cancer Cells. 1991 Feb;3(2):53-8 - PubMed
  12. BMC Cancer. 2014 Apr 30;14:304 - PubMed
  13. Drug Discov Today. 2014 Dec;19(12):1953-63 - PubMed
  14. Cell Stem Cell. 2014 Mar 6;14(3):275-91 - PubMed
  15. Cancer Sci. 2004 Dec;95(12):930-5 - PubMed
  16. Cancer Res. 2013 Mar 15;73(6):1855-66 - PubMed
  17. Cell Stem Cell. 2012 Jun 14;10(6):717-28 - PubMed
  18. BMC Cancer. 2013 Apr 08;13:182 - PubMed
  19. Stem Cells Transl Med. 2012 Oct;1(10 ):719-24 - PubMed
  20. PLoS One. 2014 Jun 24;9(6):e100249 - PubMed
  21. Stem Cell Rev. 2011 Jun;7(2):292-306 - PubMed
  22. PLoS One. 2015 Mar 09;10(3):e0116596 - PubMed
  23. Oncogene. 2013 Oct 31;32(44):5191-8 - PubMed
  24. Stem Cells Dev. 2014 Mar 15;23(6):664-75 - PubMed
  25. World J Stem Cells. 2015 Oct 26;7(9):1185-201 - PubMed
  26. Oncotarget. 2013 Oct;4(10):1698-1711 - PubMed
  27. Clin Cancer Res. 2014 Aug 1;20(15):4154-66 - PubMed
  28. J Thorac Oncol. 2016 Jul;11(7):1003-11 - PubMed
  29. Cancer Res. 2010 Dec 1;70(23 ):9937-48 - PubMed
  30. PLoS One. 2016 Jun 02;11(6):e0156595 - PubMed
  31. Stem Cells Transl Med. 2015 Sep;4(9):1033-43 - PubMed
  32. Cancer Cell. 2011 Mar 8;19(3):387-400 - PubMed
  33. PLoS One. 2014 Feb 24;9(2):e89644 - PubMed
  34. Respirology. 2013 Jul;18(5):757-64 - PubMed
  35. F1000Res. 2016 Feb 29;5:null - PubMed
  36. Stem Cell Reports. 2013 Dec 27;2(1):78-91 - PubMed

Publication Types